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The combination of cardiomyocytes (CM) and non-myocyte cardiac populations, such
as endothelial cells (EC), and mesenchymal cells (MC), has been shown to be critical for
recapitulation of the human heart tissue for in vitro cell-based modeling. However, most
of the current engineered cardiac microtissues still rely on either (i) murine/human limited
primary cell sources, (ii) animal-derived and undefined hydrogels/matrices with batch-to-
batch variability, or (iii) culture systems with low compliance with pharmacological high-
throughput screenings. In this work, we explored a culture platform based on alginate
microencapsulation and suspension culture systems to develop three-dimensional (3D)
human cardiac microtissues, which entails the co-culture of human induced pluripotent
stem cell (hiPSC) cardiac derivatives including aggregates of hiPSC–CM and single cells
of hiPSC–derived EC and MC (hiPSC–EC+MC). We demonstrate that the 3D human
cardiac microtissues can be cultured for 15 days in dynamic conditions while maintaining
the viability and phenotype of all cell populations. Noteworthy, we show that hiPSC–
EC+MC survival was promoted by the co-culture with hiPSC–CM as compared to the
control single-cell culture. Additionally, the presence of the hiPSC–EC+MC induced
changes in the physical properties of the biomaterial, as observed by an increase
in the elastic modulus of the cardiac microtissue when compared to the hiPSC–CM
control culture. Detailed characterization of the 3D cardiac microtissues revealed that
the crosstalk between hiPSC–CM, hiPSC–EC+MC, and extracellular matrix induced
the maturation of hiPSC–CM. The cardiac microtissues displayed functional calcium
signaling and respond to known cardiotoxins in a dose-dependent manner. This study
is a step forward on the development of novel 3D cardiac microtissues that recapitulate
features of the human cardiac microenvironment and is compliant with the larger
numbers needed in preclinical research for toxicity assessment and disease modeling.
Keywords: hiPSC, cardiomyocytes, endothelial cells, fibroblasts, engineered cardiac tissues,
microencapsulation, 3D culture
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INTRODUCTION
The development of reliable human in vitro cardiac tissues
that better mimic the physiology of the human heart is critical
to bridge the gap between the animal models currently used
in preclinical research and the human clinical setting. Human
induced pluripotent stem cells (hiPSCs) have emerged as a
relevant tool for human in vitro cardiac cell-based modeling,
mainly due to (i) the human origin, (ii) the unlimited proliferative
capacity, (iii) the ability to differentiate into different cardiac
cell lineages, and (iv) the potential for personalized (patient-
specific) medicine.
Recapitulation of the human heart microenvironment
in physiological or pathophysiological context for in vitro
cell-based modeling requires the utilization of the different
cellular populations that compose the human heart, namely,
cardiomyocytes (CM), endothelial cells (EC), and mesenchymal
cells (MC; which comprise mainly cardiac fibroblasts, pericytes,
and smooth muscle cells). Although there is a general consensus
that CM constitute approximately 30% of the mammalian
heart, estimated frequencies of the other populations have been
involved in some controversy (Zhou and Pu, 2016). One of
the reasons for this controversy is not only the interspecies
or intertissue variations but also the dynamic turnover of
the human heart during aging (Zhou and Pu, 2016). For
example, in the postnatal period, CM represent the majority
of the cardiac cells (66%), as opposed to the 30% in the adult
mammalian heart (Bergmann et al., 2015). Another reason for
this controversy is that divergent results have been obtained
using different analytical tools. Nevertheless, the proximity
between these different cell populations enables for intercellular
communication mediated by paracrine factors, cell–cell
interactions, and/or extracellular matrix (ECM) deposition
(Kofron and Mende, 2017). Thus, the derivation of these cellular
components from hiPSC has been pursued by our group and
others. Nevertheless, current protocols for generation of CM
from hiPSC (hiPSC–CM) result in cells with an immature
phenotype, showing metabolic, structural, and functional
characteristics that more closely resemble fetal CM rather than
adult CM (Correia et al., 2017). Studies with three-dimensional
(3D) hiPSC–derived engineered cardiac tissues have shown
a positive impact of cardiac non-myocyte populations (EC
and MC) on hiPSC–CM structural and functional maturation
(Burridge et al., 2014; Masumoto et al., 2016; Ravenscroft et al.,
2016; Giacomelli et al., 2017, 2020). However, most of these
studies have either used simplistic 3D spheroid configurations
(Ravenscroft et al., 2016; Giacomelli et al., 2017, 2020) and/or
hydrogels composed of undefined matrix components, such
as MatrigelTM (Thavandiran et al., 2013; Burridge et al., 2014;
Masumoto et al., 2016; Nakane et al., 2017). Moreover, the current
methodologies for production of such cardiac tissue models are
still limited due to (i) low throughput of aggregation protocols
dependent of 96-well plate forced aggregation (Ravenscroft
et al., 2016; Giacomelli et al., 2017, 2020); (ii) dependence
on microfabrication tools (Thavandiran et al., 2013; Nakane
et al., 2017); and (iii) low-throughput hydrogel encapsulation
techniques (Burridge et al., 2014; Masumoto et al., 2016). Thus,
further effort should be performed to develop protocols that
enable the scalable production of a biologically relevant hiPSC-
derived cardiac tissue model in defined conditions for further
implementation of large pharmacological screenings.
In this work, we aim to recapitulate human heart
microenvironment features through the design of a 3D human
cardiac microtissue by exploring a culture platform based on
xeno-free alginate microencapsulation of hiPSC–CM aggregates
and single cells of hiPSC–derived EC and MC (hiPSC–EC+MC).
We characterize the 3D hiPSC–derived cardiac microtissue at
the phenotypic, structural, and functional levels and performed a
proof-of-concept toxicological analysis.
MATERIALS AND METHODS
hiPSC Culture and Differentiation Into
Cardiovascular Lineages
hiPSC Expansion
In this study, hiPSC line DF19-9-11T.H from WiCell was
used. hiPSCs were cultured on Matrigel R© (Corning)–coated
plates in mTESR1 medium (STEMCELL Technologies,
hereafter designated as expansion medium) at 37◦C, in a
humidified atmosphere of 5% CO2 (vol/vol) in air. Cells were
routinely subcultured when reaching 80% confluence using
Versene (Thermo Fisher Scientific) as described by our group
(Correia et al., 2016).
hiPSC–CM Differentiation
Differentiation of hiPSCs into CM was performed using the
3D protocol described before by our group (Correia et al.,
2018). Briefly, hiPSCs were cultured as monolayers as described
in section “hiPSC Expansion,” and differentiation into CM
was initiated when cell confluence reached 80 to 90%. At
this timepoint (day 0), expansion medium was replaced by
RPMI medium (Thermo Fisher Scientific) supplemented with
B27 without insulin (RPMI/B27, Thermo Fisher Scientific),
12 µM CHIR99021 (Tocris), 80 ng/mL activin A (PeproTech),
and 50 µg/mL ascorbic acid (Sigma–Aldrich). After 24 h,
the medium was replaced by RPMI/B27 supplemented with
5 µM IWR-1 (Sigma–Aldrich) and 50 µg/mL ascorbic acid
(Sigma–Aldrich). At day 3 (72 h after differentiation induction),
medium was exchanged for RPMI/B27 supplemented with
5 µM IWR-1. At day 7, cell monolayers were dissociated
by incubation with TrypLE Select (Thermo Fisher Scientific)
for 5 min at 37◦C, followed by addition of culture medium
(RPMI/B27) and centrifugation at 220 × g for 5 min at room
temperature (RT, 18◦C–20◦C). Single cells were then inoculated
in AggreWellTM400Ex plates (Stem Cell Technologies) at
1,500 cells/microwell, centrifuged at 100 × g for 3 min at
RT, and cultured in RPMI/B27 medium. 2 days after seeding,
the generated cell aggregates were transferred to shake flasks
(i.e., Erlenmeyer) and cultured in RPMI/B27 medium at an
agitation rate of 90 rpm for additional 6 days (total culture
time, 15 days). Medium was replaced every 2 days. During
differentiation period, cells were cultured at 37◦C, in a humidified
atmosphere of 5% CO2 (vol/vol) in air. At day 15, hiPSC–CM
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aggregates were dissociated, counted by trypan blue exclusion
assay (see section “Cell Counting, Viability, and Metabolic
Activity”), and characterized by flow cytometry (see section “Flow
Cytometry of hiPSC–CM”). These hiPSC–CM aggregates were
then encapsulated in alginate as described below (see section “3D
hiPSC–Derived Cardiac Microtissue Culture”).
hiPSC–EC+MC Differentiation
Human iPSCs were propagated as described in section “hiPSC
expansion” and endothelial/mesenchymal differentiation was
induced according to the protocol published by Giacomelli et al.,
2017. Briefly, hiPSCs were seeded at 12.5 × 103 cells/cm2 on
the day before starting the differentiation (day -1). At day
0, cardiac mesoderm was induced by changing the medium
to APEL-LI medium (Thermo Fisher Scientific), supplemented
with a mixture of cytokines (20 ng/mL BMP4, PeproTech;
20 ng/mL activin A, PeproTech; and 1.5 µM GSK3 inhibitor
CHIR99021, Tocris). At day 3, cytokines were removed, and
vascular endothelial growth factor (VEGF; 50 ng/mL, PeproTech)
was added. APEL-LI medium supplemented with VEGF was
refreshed every 3 days until day 10. During differentiation cells
were cultured at 37◦C, in a humidified atmosphere of 5% CO2
(vol/vol) in air. At day 10, hiPSC–EC+MC were harvested using
TrypLE Select, counted by trypan blue exclusion assay (see
section “Cell Counting, Viability, and Metabolic Activity”), and
characterized by flow cytometry (see section “Flow Cytometry
of hiPSC–CM”). These cells were then encapsulated in alginate
as described below (see section “3D hiPSC–Derived Cardiac
Microtissue Culture”).
3D hiPSC–Derived Cardiac Microtissue
Culture
The 3D hiPSC–derived cardiac microtissues were
developed using microencapsulation technology. Alginate
microencapsulation of cells/aggregates was performed as
described previously (Rebelo et al., 2015, 2018; Estrada
et al., 2016). More specifically, hiPSC–CM aggregates [total
of 1.2 × 104 aggregates corresponding to approximately
5 × 106 cells, counted by trypan blue exclusion assay (see
section “Cell Counting, Viability, and Metabolic Activity”)], were
collected from suspension cultures and mixed with single cells
of hiPSC–EC+MC (10 × 106 cells, harvested from adherent
cultures and counted by trypan blue exclusion method) for a ratio
of 1:2 (hiPSC–CM:hiPSC–EC+MC). The suspension of hiPSC–
CM aggregates and hiPSC–EC+MC single cells was centrifuged
at 300 × g, for 5 min at RT, and resuspended in 1 mL of 1.1%
(wt/vol) of 1:1 mixture of Ultrapure MVG alginate (NovaMatrix,
Pronova Biomedical) and NOVATACH MVG GRGDSP peptide-
coupled alginate (NovaMatrix, Pronova Biomedical) dissolved
in NaCl 0.9% (wt/vol) solution. Cell microencapsulation was
performed using an electrostatic bead generator (VarV1, Nisco),
to produce beads of approximately 1,500 µm in diameter. The
alginate droplets were cross-linked in a 100 mM CaCl2/10 mM
HEPES (pH 7.4) solution for 7 min, washed three times in a 0.9%
(wt/vol) NaCl solution and then equilibrated in culture medium
[1:1 mixture of RPMI medium supplemented with B27 without
insulin and Endothelial Cell Growth Medium 2 (Promocell)].
The microencapsulated microtissues were then transferred to
shake flasks (50 mL of culture, approximately 14 capsules/mL)
and cultured in suspension at 90 rpm in a humidified incubator
with 5% (vol/vol) CO2 in air at 37◦C for 15 days. Medium
exchange was performed every 2 to 3 days (three times a week).
Monocultures of hiPSC–CM (5 × 106 cell/mL of alginate) and
co-cultures of hiPSC–EC+MC (10 × 106 cell/mL of alginate)
were also microencapsulated and used as controls.
Cell Culture Characterization
Flow Cytometry of hiPSC–CM
Human iPSC–CM aggregates were harvested from culture and
dissociated with TypLETM Select for 5 min at 37◦C with agitation.
Afterward, single cells were washed twice with Dulbecco’s
phosphate-buffered saline (DPBS) (Thermo Fisher Scientific),
and 5 × 105 cells were incubated in the dark with one of
the following conjugated antibodies for 1 h at 4◦C: SIRPα/β
(CD172a/b-PE, BioLegend, diluted 1:20 in DPBS), VCAM
(CD106-PE, BD Biosciences, diluted 1:5 in DPBS), or isotype
control immunoglobulin G1 (IgG1),κ-PE (BD Biosciences,
diluted 1:5 in DPBS). For detection of intracellular marker
(Troponin T, Thermo Fisher Scientific), cells were fixed and
permeabilized with Inside Stain Kit (Miltenyi Biotec) according
to the manufacturer’s instructions. Cells were incubated with
primary antibody (diluted 1:200 in InsidePerm) for 10 min at RT,
washed with InsidePerm, and incubated with secondary antibody
anti–mouse IgG Alexa Fluor 488 (diluted 1:200 in InsidePerm)
for 10 min at RT. Cells were washed with InsidePerm and
analyzed by a CyFlow R© space (Partec GmbH). Ten thousand
events were analyzed per sample.
Flow Cytometry of hiPSC–EC+MC
Human iPSC–EC+MC were harvested from culture by
dissociation with TypLETM Select for 5 min at 37◦C. Afterward,
single cells were washed twice with DPBS, and 5× 105 cells were
processed as described in section “Flow Cytometry of hiPSC–
CM.” Primary antibodies used were CD31 (Agilent, diluted 1:50
in DPBS), VE-cadherin (R&D Systems, diluted 1:13 in DPBS),
vimentin (Abcam, diluted 1:100 in InsidePerm), or α-smooth
muscle actin (α-SMA; Agilent, diluted 1:100 in InsidePerm).
Secondary antibody used was anti–mouse IgG Alexa Fluor
488 (diluted 1:200 in InsidePerm). Cells were analyzed by a
CyFlow R© space (Partec GmbH). Ten thousand events were
analyzed per sample.
Cell Counting, Viability, and Metabolic Activity
Viable cells were quantified by trypan blue exclusion, as described
elsewhere (Abecasis et al., 2017). For viability assessment, the
enzyme substrate fluorescein diacetate (FDA, Sigma–Aldrich)
and the DNA dye propidium iodide (PI, Sigma–Aldrich) were
used (Serra et al., 2011; Silva et al., 2015). In this method,
direct staining of the live aggregates was performed followed
by observation at the fluorescence microscope (DMI6000, Leica,
Wetzlar, Germany), as described elsewhere (Serra et al., 2011).
Cells that accumulated the metabolized product of FDA were
considered live, and cells stained with PI were considered dead.
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For evaluation of metabolic activity, the reduction capacity
of the cultures was measured by PrestoBlue R© Viability
Reagent reduction assay (Life Technologies), according to
the manufacturer’s instruction. PrestoBlue R© reagent is reduced
by viable cells and becomes highly fluorescent. This color change
can be detected using fluorescence measurements. Samples of
2 to 5 capsules were taken from suspension agitated cultures
into a 96-well plate. The microencapsulated cells were incubated
with PrestoBlue R© reagent for 3 h at 37◦C. After this period,
the supernatant was collected, and the fluorescence was read at
560-nm excitation and 590-nm emission in the microplate reader
Infinite R©200 PRO (NanoQuant, Tecan Trading AG).
Gene Expression Analysis
Alginate microcapsules of cardiac microtissues were dissolved
with a chelating solution (sodium citrate 50 mM, sodium
chloride 100 mM) and centrifuged at 300 × g for 5 min at
RT. Pellets were snap-frozen and kept at -80◦C until RNA
isolation. Total RNA was isolated with the High Pure RNA
Isolation Kit (Roche). The RNA was quantified, and purity
checked by Nanodrop 2000c (Thermo Scientific). RNA reverse
transcription to double-stranded cDNA was performed with
the Transcriptor High Fidelity cDNA Synthesis Kit (Roche).
Real-time quantitative polymerase chain reaction (RT-qPCR)
was conducted with the LightCycler 480 Probes Master system
(Roche) using TaqMan Gene Expression Assays (Thermo Fisher
Scientific). The performed cycles were as follows: preincubation
at 95◦C for 10 min, 45 cycles of amplification with denaturation at
95◦C for 15 s, and annealing at 60◦C for 1 min; extension at 72◦C
for 5 min. Threshold cycles (Ct) were automatically determined
by the LightCycler 480 Software (Roche). All data were analyzed
using the 2−1 1 Ct method for relative gene expression analysis
(Livak and Schmittgen, 2001). Changes in gene expression were




Microencapsulated cells were collected from culture and fixed
in 4% (wt/vol) formaldehyde with 4% (wt/vol) sucrose in
phosphate-buffered saline (PBS) for 20 min at RT. For
cryosectioning preparation, samples were dehydrated in 30%
(wt/vol) sucrose overnight at 4◦C, embedded in Tissue-Tek R©
O.C.T. (Sakura) and frozen at -80◦C. The frozen samples were
sliced with a thickness of 10 µm in a cryostat (Cryostat CM
3050 S, Leica). The cryosections were permeabilized for 10 min
with 0.1% (vol/vol) Triton X- 100 (Sigma–Aldrich) and blocked
with 0.2% (wt/vol) fish-skin gelatin (FSG; Sigma–Aldrich) in PBS
for 30 min. Primary and secondary antibodies were prepared
in 0.125% (wt/vol) of FSG in PBS and incubated for 2 h. The
primary antibodies used were as follows: cardiac troponin T
(cTnT, Thermo Fisher Scientific, 1:200), sarcomeric α-actinin
(Sigma–Aldrich, 1:200), collagen I (Abcam, 1:100), and collagen
IV (Abcam, 1:100). Secondary antibodies used were as follows:
anti–mouse IgG Alexa Fluor 594, anti–rabbit IgG Alexa Fluor
594, anti–mouse IgG Alexa Fluor 488, anti–rabbit IgG Alexa
Fluor 488, and anti–mouse IgG Alexa Fluor 594 (all from Thermo
Fisher Scientific, 1:500). The samples were mounted in Prolong R©
Gold reagent containing DAPI (Life Technologies). Samples were
visualized using a confocal fluorescence microscope (SP5, Leica).
Whole mount
Microencapsulated cells were collected from culture and fixed
in 4% (wt/vol) formaldehyde with 4% (wt/vol) sucrose in PBS
for 20 min at RT. Samples were permeabilized and blocked
with 1% (wt/vol) Triton X-100 solution/0.2% FSG for 2 h at
RT and subsequently incubated overnight at RT with primary
antibodies (CD31, Agilent; vimentin, Abcam) diluted in 0.1%
(wt/vol) TX-100 and 0.125% (wt/vol) FSG. Samples were then
washed three times with DPBS and incubated with secondary
antibodies (AlexaFluor 488 goat anti–mouse IgG, AlexaFluor
549 goat anti–rabbit IgG, Thermo Fisher Scientific) diluted
in 0.125% (wt/vol) FSG, for 5 h at RT. After three washes
with DPBS, cell nuclei were counterstained with DRAQ5
(Thermo Fisher Scientific). Samples were visualized using
light-sheet fluorescence microscopy (LSFM) or multiphoton
immunofluorescence microscopy (IFM) as described previously
(Estrada et al., 2016).
Transmission Electron Microscopy
Microencapsulated cells were fixed in 4% (wt/vol)
paraformaldehyde with 4% (wt/vol) sucrose in DPBS for
20 min at RT. Fixed samples were washed twice with DPBS
and stored at 4◦C. Second fixation was performed using 2%
(vol/vol) formaldehyde (EMS) and 2.5% (vol/vol) glutaraldehyde
(Polysciences) in 0.1 M phosphate buffer (PB), for 1 h at 4◦C.
Cells were washed with PB and embedded in 2% low melting
point agarose (OmniPur) for further processing. Postfixation
was performed with 1% (wt/vol) osmium tetroxide (EMS) in
0.1 M PB for 30 min on ice in the dark. After two washes with
0.1 M PB and two washes with water, samples were incubated
with 1% aqueous tannic acid (wt/vol; EMS) for 20 min on ice.
After five washes with water, samples were contrasted with
0.5% aqueous uranyl acetate (wt/vol), 1 h on ice in the dark.
Dehydration was performed using a graded series of ethanol
(30, 50, 75, 90, and 100%), and samples were embedded in
Embed-812 epoxy resin (EMS). Ultrathin sections were cut
on a Leica UC7 ultramicrotome. Sections were collected on
grids coated with 1% (wt/vol) formvar (Agar Scientific) in
chloroform (VWR) and stained with 1% (wt/vol) uranyl acetate
and Reynolds lead citrate, for 5 min each. Images were taken on a
Hitachi H-7650 at 100 keV equipped with a XR41M mid mount
AMT digital camera.
Calcium Imaging
Calcium imaging was performed using the Fluo-4 DirectTM
Calcium Assay Kit (Thermo Fisher Scientific) according to
the manufacturer’s instructions. Briefly, microencapsulated cells
were transferred onto four-well µslides (Ibidi). The samples
were loaded with the calcium indicator dye Fluo-4 (diluted 1:2
in culture medium) for 45 min at 37◦C plus 15 min at RT
and washed twice with culture media. Analysis was performed
under temperature control (37◦C), and spontaneous calcium
activity was recorded. Cells were analyzed alone or exposed
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to norepinephrine (60 µM, norepinephrine bitartrate, Sigma–
Aldrich). Alginate microcapsules were imaged using a spinning
disk confocal microscope (Revolution XD, Andor), and 30-
s videos were acquired using Micro-Manager 1.4 software.
Fluorescence videos were analyzed by manually selecting
each individual aggregate within the alginate microcapsule
using ImageJ open source software (Rasband, WS, ImageJ,
United States National Institutes of Health, Bethesda, MD,
United States, http://imagej.nih.gov/ij/, 1997–2018). Extracted
data were treated using a developed in-house script in
MATLAB (MathWorks). Briefly, data were normalized to
baseline fluorescence (1F/F0), and each peak was analyzed
for the following parameters: amplitude, rise time, maximal
upstroke velocity, time to 50 and 80% decay, maximal decay
velocity, and time between peaks, as previously described
(Abecasis et al., 2019).
Cardiotoxic Drug Exposure
After 15 days of culture, microencapsulated cardiac microtissues
and hiPSC–CM controls were harvested from suspension culture
and transferred to 96-well plate (two to five capsules were
inoculated per well). Cells were first evaluated for metabolic
activity and cell viability as explained in section “Cell Counting,
Viability, andMetabolic Activity.” Then, the cultures were washed
twice with DPBS and incubated with doxorubicin or paclitaxel
(0.1, 0.5, 1, 5, 10, 50, and 100 µM, MedChemExpress) for 72 h in a
humidified incubator with 5% (vol/vol) CO2 in air at 37◦C under
agitation (90 rpm). After this period, cells were assessed again for
metabolic activity and cell viability (see section “Cell Counting,
Viability, and Metabolic Activity”).
Atomic Force Microscopy
Atomic force microscopy (AFM) characterization was performed
to compare surface topography and mechanobiological behavior
of alginate capsules and the cardiac microtissues 15 days
after microencapsulation. Samples were collected and fixed as
indicated previously (see section “Whole Mount”). Fixed samples
were washed twice with DPBS and stored at 4◦C until AFM
characterization. Alginate microcapsules were embedded in 2%
(wt/vol) high-melting-temperature agarose (Lonza), forming a
thin film, which was kept hydrated up to AFM analysis. All
measurements were performed in an Asylum Research MFP-
3D Stand Alone system, whereas samples were immersed in
PBS buffer. Surface topography measurements were acquired in
alternate contact mode using commercially available AFM probes
(Olympus BL-AC40-TS; f 0 = 110 kHz; k = 0.09 N/m). Acquisition
of load–unload force curves (force spectroscopy) was performed
with the same probes, after previous calibration through thermal
tuning (Green et al., 2004). Asylum Research’s analysis software
packages loaded in IGOR Pro software (WaveMetrics) were
used to generate low-order plane-fitted topography images
and determine average pore diameter. Load–unload curves
were analyzed in the same software, being considered curves
from, at least, three capsules per condition. Apparent elastic
moduli of the samples were determined by fitting the elastic
Sneddon contact model for conical indenters (Sneddon, 1965) to
the unload curves.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism6
(GraphPad Software Inc.). Values are represented as
mean ± standard error of the mean (SEM) of measurements or
assays in independent alginate microcapsules from one or two
independent differentiation batches, as stated in the respective
results figures. Statistical significance was determined by Student
t test. p < 0.05 was considered as statistically significant.
RESULTS
Establishment of a 3D hiPSC–Derived
Cardiac Microtissue Model
In this work, we developed a 3D cardiac microtissue model
using CM, EC, and MC derived from hiPSC microencapsulated
in alginate. Differentiation of hiPSC into CM lineage was
performed as previously described by our group (Correia et al.,
2018), yielding 3D aggregates of hiPSC–CM with uniform
size distribution (average size: 142 ± 26 µm) and high cell
viability (Supplementary Figure 1A). Noteworthy, the hiPSC–
CM aggregates showed high CM purity by the end of the
differentiation protocol, with majority of the cells expressing
SIRPα/β (81% ± 1%), VCAM-1 (73% ± 5%) and cTnT (77%)
at day 15 of differentiation (Supplementary Figure 1B). In
parallel, hiPSC were also differentiated into EC and MC,
using a monolayer-based differentiation protocol developed by
other authors (Giacomelli et al., 2017). This protocol generated
a mixed population of cells expressing CD31 (27% ± 4%),
VE-Cad (21% ± 3%), vimentin (90% ± 1%), and α-SMA
(35%± 12%), which are markers for EC (CD31 and VE-Cad) and
fibroblasts and/or vascular smooth muscle cells (vimentin and
α-SMA; hereafter designated as hiPSC–EC+MC, Supplementary
Figure 1C). After 10 days of differentiation, hiPSC–EC+MC
were harvested and co-cultured with hiPSC–CM aggregates,
collected at day 15, within alginate microcapsules.
Cell/aggregate microencapsulation in alginate (1:1 mixture
of Ultrapure MVG alginate and NOVATACH MVG GRGDSP
peptide-coupled alginate; see section “3D hiPSC–Derived Cardiac
Microtissue Culture”) was carried out using the methodology
already reported by our group (Rebelo et al., 2015, 2018; Estrada
et al., 2016). A preliminary study was performed to evaluate the
impact of aggregate concentration [hiPSC–CM aggregates/mL
of 1.1% (wt/vol) alginate solution] on the percentage of
empty capsules generated. Results showed that the percentage
of empty capsules was reduced when using a concentration
of at least 12,000 aggregates/mL of alginate (Supplementary
Figure 1D), and thus this condition was selected to perform the
microencapsulation of cell aggregates. For the generation of 3D
microencapsulated cardiac microtissues, hiPSC–CM aggregates
were mixed with hiPSC–EC+MC single cells in a 1:2 cellular
ratio in order to obtain a cell composition similar to what has
been reported for human adult heart: approximately 33% CM,
17% EC, and 50% MC (Bergmann et al., 2015). The cell/aggregate
suspension was then microencapsulated in alginate mixture
(hereafter designated as cardiac microtissues; Figure 1A).
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FIGURE 1 | (A) Schematic representation of the alginate microencapsulation protocol for cardiac microtissue (µtissue) formation and respective control cultures
hiPSC–CM and hiPSC–EC+MC. Capsules were maintained in dynamic suspension culture until day 15 post-microencapsulation for further microtissue
characterization. (B,C) Evaluation of cell viability and metabolic activity for the cardiac microtissue (µtissue) and control cultures (hiPSC–CM and hiPSC–EC+MC).
(B) Viability analysis of the three microencapsulated cell cultures throughout time (days 1, 7, and 15), stained with fluorescein diacetate (FDA—live cells, green) and
propidium iodide (PI—dead cells, red). Microcapsules are marked with white dashed line. Scale bar: 200 µm. (C) Metabolic activity of the three microencapsulated
cell cultures during time (days 2, 7, and 15), measured by the capacity of reduction of Presto-BlueTM Viability Reagent, normalized by capsule and to hiPSC–CM
culture condition on day 2. Data represented as mean ± SEM; n = 3 independent measurements from one differentiation batch; *p < 0.05, **p < 0.005.
Microencapsulation of hiPSC–CM aggregates alone and hiPSC–
EC+MC single cells was also performed and used as controls
(Figure 1A). All cell microencapsulated conditions (cardiac
microtissues, hiPSC–CM aggregates, and hiPSC–EC+MC) were
cultured in agitated suspension conditions for additional 15 days.
Cell viability and metabolic activity of all cultures were
evaluated after 1, 7, and 15 days of microencapsulation by
live/dead staining and PrestoBlueTM assay (Figures 1B,C). The
results showed that cardiac microtissues maintained high cell
viability throughout culture time, displaying significantly higher
metabolic activities than both control cultures (Figures 1B,C;
at day 15 µtissue vs. hiPSC–CM p = 0.0074 and µtissue
vs. hiPSC–EC+MC p < 0.001). This result is also related
with the higher number of cells inoculated within the cardiac
microtissues microcapsules when compared to the values used
in control cultures. Noteworthy, our data also show evidence
of the protective effect of hiPSC–CM on hiPSC–EC+MC
survival. In particular, we observed a significant drop in viability
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FIGURE 2 | Topographical characterization of the cardiac microtissue and the alginate microcapsule at day 15 post-microencapsulation. Surface topography (A)
and pore size (B; n = 61 independent measurements from two differentiation batches) of the alginate capsule by atomic force microscopy (AFM). (C) Mechanical
characterization (elastic modulus, E) for the microtissue (µtissue; triculture), hiPSC–CM and the empty alginate capsule via AFM. Data represented as mean ± SEM;
n > 40 independent measurements from two differentiation batches; *p < 0.05, ****p < 0.0001.
and metabolic activity from day 7 onward in hiPSC–EC+MC
cultures, contrasting with cardiac microtissues and hiPSC–CM
monocultures that maintained high cell viability and metabolic
activity through time (Figures 1B,C). The significant increase
in metabolic activity of cardiac microtissues from days 7 to
15 may indicate either an increase in cell numbers due to cell
proliferation of non-myocyte cells or an increase in metabolic
capacity of hiPSC–CM aggregates, as previously described by our
group (Correia et al., 2018). In fact, a similar profile was observed
in hiPSC–CM control culture that showed a peak in metabolic
activity at day 15.
In addition, characterization of mechanical and topographical
properties was performed via AFM in empty alginate capsules
and encapsulated cultures (hiPSC–CM aggregates and cardiac
microtissue). AFM topographical imaging evidenced an alginate
porous surface structure (Figure 2A), with heterogeneity,
particularly in the microcapsule constructs containing hiPSC–
CM aggregates and cardiac microtissue when compared
with cell-free capsules (data not shown), demonstrating
cell–biomaterial interaction and its impact on morphology
and topography. Additionally, analysis of the AFM images
showed that the microcapsule average pore diameter was
579.6 ± 137.0 nm (Figures 2A,B), enabling effective diffusion
of nutrients, metabolites, and drugs into the microcapsule.
Furthermore, characterization was performed via load–unload
force curves (force spectroscopy) for the empty alginate capsules
and encapsulated at the last day of culture (Figure 2C).
The calcium RGD-alginate microcapsule biomaterial alone
denoted an elastic modulus of 132.3 ± 53.7 kPa, significantly
superior to the cellularized constructs (Figure 2C). This
seems to indicate that the microenvironment in the presence
of the cells is less stiff, when compared to the biomaterial
alone. In addition, in comparison to the encapsulated
hiPSC–CM aggregates, the cardiac microtissue’s elastic
modulus is significantly higher (Figure 2C), exhibiting a
stiffer microenvironment more resistant to deformation,
which may be consistent with a remodeling of the cardiac
microenvironment resulting from the presence of the
non-myocyte cells.
Phenotypic, Structural, and Functional
Characterization of the 3D
hiPSC-Derived Cardiac Microtissue
Cardiac microtissues were characterized at phenotypic,
structural, and functional level and compared with hiPSC–
CM. LSFM was used to confirm the presence of the non-myocyte
cellular populations, namely, EC (stained for CD31 and VE-
cadherin) and MC (stained for vimentin and α-SMA), as single
cells within alginate microcapsules after 15 days of culture
(Figure 3A). Vimentin and α-SMA staining was also observed
within the aggregates of the cardiac microtissues either by
LSFM (Figure 3A) and IFM of the cryosections (Figure 3B).
These MC most likely originate from the percentage of cells
in the CM differentiation protocol that do not express cardiac
specific markers (Supplementary Figure 1B), because these
stainings were also observed in the hiPSC–CM aggregates
control culture (Figures 3A,B). Cardiac microtissues showed
expression and organization of sarcomeric structural proteins
(cTnT and α-actinin) after 15 days of culture (Figure 3C). In
addition, f-actin counterstaining clearly illustrates assembly
and organization of myofibrils (Figure 3C). Staining for
collagen I, collagen IV, and fibronectin confirmed expression
of these ECM components in cardiac microtissues by imaging
through whole-mount multiphoton microscopy (Figure 4A) and
cryosections’ confocal microscopy (Figure 4B). Noteworthy,
collagen IV staining was more noticeable inside the cardiac
microtissue alginate capsule (and outside the hiPSC–CM
aggregates; Figure 4A), when compared to hiPSC–CM control,
likely originated from the non-myocyte cells.
Gene expression analysis of cardiac microtissues by RT-
qPCR revealed an increase in expression of gene isoforms
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FIGURE 3 | Phenotypic characterization of cardiac microtissue (µtissue) and hiPSC–CM control culture by immunofluorescence microscopy at day 15.
(A) Light-sheet immunofluorescence microscopy of the whole-mount microencapsulated cardiac microtissue and hiPSC–CM. Cells were stained for endothelial cell
markers (CD31 and VE-cadherin, green) and MC markers (vimentin and α-SMA, red). Images were counterstained with DRAQ5 (nuclei, cyan). Scale bar = 100 µm.
(B,C) Immunofluorescence microscopy of cryosections of cardiac microtissue and hiPSC–CM aggregates. (B) Cells were stained for α-smooth muscle actin (α-SMA,
red). Images were counterstained with and DAPI (nuclei, blue). Scale bar = 50 µm. (C) Cells from cardiac microtissue (µtissue) were stained for sarcomeric structural
proteins (cTnT and α-actinin, red). Images were counterstained with phalloidin (f-actin, green) and DAPI (nuclei, blue). Scale bar = 50 µm.
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FIGURE 4 | Phenotypic characterization of cardiac microtissue (µtissue) and hiPSC–CM by immunofluorescence microscopy after 15 days’ culture. Cells were
stained for ECM proteins (collagen I, collagen IV, and fibronectin). Images are counterstained with DAPI. (A) Multiphoton immunofluorescence microscopy of the
whole-mount microencapsulated cardiac microtissue and control hiPSC–CM. Scale bar = 50 µm. (B) Immunofluorescence microscopy of the cryosections of
cardiac microtissue and control hiPSC–CM monoculture for characterization of the hiPSC–CM aggregates. Scale bar = 50 µm.
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FIGURE 5 | Continued
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FIGURE 5 | Characterization of structural maturation of the cardiac microtissues after 15 days of culture. (A) Analysis of gene expression by RT-qPCR of specific
genes associated with cardiomyocyte structure and organization in cardiac microtissue (green) and hiPSC–CM (gray) throughout the culture time. Expression ratios
for cardiac isoforms of mature (MYL2, MYH7, and TNNI3) and immature (MYL7, MYH6, and TNNI1) phenotypes were displayed. Gene expression was normalized to
day 1. Data represented as mean ± SEM; n = 3 independent measurements from one differentiation batch. (B) Transmission electron microscopy images of cardiac
microtissue (µtissue) and hiPSC–CM culture: (i) aligned myofibrils, composed by sarcomeres with organized Z-disks, A-bands, and I-bands; (ii) cell junctions (gap
junctions, GJ) between adjacent hiPSC–CM; and (iii) abundant mitochondria (M). Scale bar: 2 µm. (C) Analysis of sarcomere length of cardiac microtissue (µtissue,
green) and hiPSC–CM culture (gray). Data represented as mean ± SEM; n > 40 independent measurements from one differentiation batch; **p < 0.01. (D) Analysis
of myofibril alignment (as shown by myofibril angle dispersion) of cardiac microtissue (µtissue, green) and hiPSC–CM control (gray). Data represented as
mean ± SEM; n > 8 independent measurements from one differentiation batch; *p < 0.05. (E) Phenotypic characterization of cardiac microtissue (µtissue) and
hiPSC–CM culture by immunofluorescence after 15 days’ culture. Cells were stained for connexin 43 (Cx43, red). Images are counterstained with DAPI (blue). Scale
bar = 50 µm.
associated with mature sarcomeric structures when compared
to more immature isoforms (MYL2/MYL7, MYH7/MYH6,
and TNNI3/TNNI1 ratios) along culture time (Figure 5A).
Although similar profiles were observed in terms of sarcomeric
gene expression for cardiac microtissue and hiPSC–CM,
ultrastructural analysis showed differences in terms of sarcomeric
length and alignment, indicative of hiPSC–CM maturation.
Ultrastructure analyses of the cardiac microtissues show the
presence of sarcomeres with organized Z-disks, A-bands, and
I-bands by day 15 of culture (Figure 5B), which were not
observed by the beginning of the culture (data not shown).
Intercalated disks between adjacent hiPSC–CM and abundant
mitochondria were also identified (Figure 5A). Analysis of
sarcomere length and alignment from images obtained by
transmission electron microscopy (TEM) suggested improved
structural maturation of hiPSC–CM in the cardiac microtissues
compared to the control hiPSC–CM aggregates. In particular,
sarcomere length and myofibril alignment were significantly
higher in cardiac microtissues when compared to hiPSC–CM
aggregates (Figures 5C,D). In agreement, IFM of aggregate
cryosections indicated evidences of increased expression of
Cx43 in cardiac microtissues than in hiPSC–CM aggregates
(Figure 5E), which could also be indicative of improved
structural maturation of the formers, as previously described by
other studies (Hussain et al., 2013; Giacomelli et al., 2020).
Calcium imaging was performed using a fluorescent
calcium indicator (Figures 6A–F, Supplementary Figure 2
and Supplementary Video 1), enabling the evaluation of the
functionality of generated cardiac microtissues and estimation
of different calcium kinetics’ parameters. Spontaneous calcium
transients were observed in the cardiac microtissues, indicating
the presence of functional calcium handling machinery
(Figure 6B). Exposure to an adrenergic agonist (norepinephrine,
60 µM) resulted in a positive chronotropic response (Figure 6B).
Analysis of the calcium kinetics’ parameters revealed that
exposure to norepinephrine resulted in decrease in rise and decay
time (Figures 6C–F) and decrease in cycle length (Figure 6G),
demonstrating functional β-adrenergic response. Moreover,
increased expression of the L-type calcium-channel subunit
α-1C (CACNA1C) was also observed over time in the cardiac
microtissue (Figure 6H), which could be indicative of increased
calcium handling functionality in the cardiac microtissue.
To evaluate the feasibility of this cardiac microtissue
for application in toxicology, a proof-of-concept study
was performed by exposing cell microcapsules to two
chemotherapy anticancer drugs with known cardiotoxicity
effects (Figures 6H–J): doxorubicin and paclitaxel (Bovelli
et al., 2010). Our results indicate that cardiac microtissues were
sensitive to both drugs. A decrease in cell viability and metabolic
activity after exposure to doxorubicin and paclitaxel in a
concentration-dependent manner was observed (Figures 6H,I).
Noteworthy, hiPSC–CM seem to have an increased sensitivity to
doxorubicin when compared to the cardiac microtissue showing
lower metabolic activities (Figure 6H). No major differences
in sensitivity were observed between hiPSC–CM and the
cardiac microtissue for the paclitaxel exposure (Figure 6I), both
displaying low metabolic activities for concentrations greater
than 10 µM. Representative images of live/dead staining after
exposure to doxorubicin and paclitaxel are shown in Figure 6J.
DISCUSSION
Drug development is a long and costly process with low
success rates, in which cardiotoxicity is one of the major
reasons for failure (Eder et al., 2016). Current preclinical
testing relies mainly on (i) in vitro systems that have low
compliance with high-throughput screenings; or (ii) cost-
and labor-intensive animal models that differ from human
physiology and should be restricted to a minimum use from an
ethical point of view (Eder et al., 2016). The development of
biologically relevant and reliable human in vitro cardiac tissue
models using hiPSC derivatives may circumvent some of these
limitations, allowing better understanding of human cardiac
diseases and improvement of the assessment of cardiotoxicity
of new drugs in a human setting. In this study, we developed
a novel in vitro 3D human cardiac microtissue by combining
hiPSC–CM aggregates and hiPSC–EC+MC single cells inside
alginate microcapsules.
Cell microencapsulation technology has been thoroughly
explored by our group for different applications in (stem)
cell bioprocessing, such as expansion/cryopreservation of hESC
(Serra et al., 2011), culture of hepatocyte spheroids (Tostões
et al., 2011; Rebelo et al., 2015), and tumor in vitro modeling
(Estrada et al., 2016; Rebelo et al., 2018), showing positive
impact on cell viability, phenotype and functionality. The
small spherical capsules (approximately 1,500 µm in diameter)
confer protection to shear stress, while creating an extracellular
environment that enables diffusion of nutrients and soluble
factors through the hydrogel structure and prevents the
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FIGURE 6 | Continued
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FIGURE 6 | (A–F) Characterization of calcium handling kinetics of cardiac microtissue by fluorescent calcium imaging at day 15 post-microencapsulation.
(A) Representative images of the maximum and minimum fluorescence of the videos analyzed. (B) Representative profile of spontaneous calcium transients in the
cardiac microtissue: without drug exposure and with exposure to 60 µM of norepinephrine. (C–F) Calcium kinetics parameters obtained from the analysis of the
transients: (C) rise time, (D) time to 50% decay, (E) time to 80% decay, and (F) cycle length. Data represented as mean ± SEM; n > 8 independent measurements
from one differentiation batch; *p < 0.05, ****p < 0.0001. (G) Analysis of gene expression by RT-qPCR of voltage-dependent L-type calcium channel subunit α-1C
(CACNA1C). Data represented as mean ± SEM; n = 3 independent measurements from one differentiation batch. (H–J) Evaluation of metabolic activity and cell
viability of the cardiac microtissue (µtissue) after 72-h exposure to doxorubicin or paclitaxel. (H,I) Dose–response curve showing the effect of (H) doxorubicin and (I)
paclitaxel on cell metabolic activity measured by the capacity of reduction of Presto-BlueTM Viability Reagent. Values were normalized to metabolic activity of cardiac
microtissue before exposure. Data represented as mean ± SEM; n = 3 independent measurements from one differentiation batch. (J) Representative images of cell
viability analysis of cardiac microtissues and hiPSC–CM after 72-h exposure to 10 µM of doxorubicin (Doxo) and 50 µM of paclitaxel (Pacli), stained with fluorescein
diacetate (FDA—live cells, green) and propidium iodide (PI—dead cells, red). Scale bar: 200 µm.
washout of ECM and soluble factors (Tostões et al., 2011;
Serra et al., 2012; Rebelo et al., 2015, 2018; Estrada et al.,
2016); therefore, a microenvironment is generated in which
the effect of paracrine interactions between the different
cardiac cell types (hiPSC–CM and hiPSC–EC+MC) can be
studied. The pore size estimated by AFM (579.6 ± 137.0 nm)
seem to support that appropriate diffusion of nutrients and
oxygen has occurred, as well as the proper diffusion of the
cardiotoxic drugs in the proof-of-concept toxicology study.
Additionally, alginate is biomaterial with no animal-derived
components, and the combination of AggreWell technology
and alginate microencapsulation is compatible with agitated
suspension cultures (e.g., shake flasks and bioreactors) and
high-throughput screening studies. Furthermore, if required,
separation of both cell types (aggregates and single cells)
is facilitated by the end of the co-culture period, enabling
the study and characterization (e.g., flow cytometry, mass
spectrometry, and functional characterization, etc.) of each
population individually without the need of adding extra cell
dissociation steps that usually compromise cells’ viability and
quality attributes.
Another main benefit of cell microencapsulation technology
is the possibility of designing the scaffold environment
with specific biomaterials and/or hydrogels that can be
further functionalized to create tailored microenvironments
that regulate cell fate decisions, i.e., improved cell viability,
expansion/differentiation, and/or functionality. In this study,
a mixture of peptide-coupled alginate containing RGD motifs
(arginine–glycine–aspartic acid) was used to promote attachment
and survival of anchorage-dependent single cells (hiPSC–
EC+MC), as previously described for in vitro cardiac cell-
based models (Shachar et al., 2011). Our designed hydrogel
showed to be suitable for the preservation of cell viability
and phenotype of all cardiac populations within 15 days of
culture. Noteworthy, we showed for the first time evidences
of the protective effect of hiPSC–CM on hiPSC–EC+MC
survival, similarly to what has been described for in vivo
cardiac development conditions (Hsieh et al., 2006). Our
findings may be related with paracrine factors produced by
CM known to be responsible for maintenance of non-myocyte
cells viability during in vivo cardiac development, namely,
VEGF-A, or angiopoietin (Hsieh et al., 2006). In fact, a
previous study from our group has identified expression of
angiogenic factors (including VEGF) in the secretome hiPSC–
CM aggregates (Sebastião et al., 2020). A deeper understanding
of how hiPSC–CM communicate with hiPSC–EC+MC will be
important not only to develop more physiologically relevant
cardiac tissue models but also to design advanced therapies for
cardiac regeneration.
The use of a combination of different bioimaging techniques
confirmed the organization of sarcomeric structure in hiPSC–
CM aggregates as well as the presence of the non-myocyte
cellular populations within the alginate capsule of cardiac
microtissues at day 15 of culture. Noteworthy, gene expression
analysis and ultrastructure characterization of the cardiac
microtissues showed that hiPSC–CM displayed improved
structural maturation with culture time. This result is aligned
with other studies reporting the importance of EC and CF
in enhancing the maturation of hiPSC–CM at the structural,
functional, and metabolic level. In a recent work, Giacomelli
and coworkers identified key mechanisms in the tricellular
interactions, involving cAMP/β-adrenergic and cell junction
assembly pathways (Giacomelli et al., 2020). In fact, the
microencapsulated cardiac microtissues developed herein also
showed increased expression of the gap junction protein Cx43.
Other heterotypic communication mechanisms, such as cell–
ECM interactions or paracrine effects, have also been shown
to impact on the maturation of hiPSC–CM (Fong et al., 2016;
Abecasis et al., 2019). Indeed, the alginate microencapsulation
supported the remodeling of the cells’ microenvironment,
namely, the deposition of ECM components, such as collagen
IV. However, the observed ECM deposition may have impacted
the hiPSC–CM maturation not only directly through cell–
ECM communication but also through the changes in the
physical properties of the supporting biomaterial. The results
from AFM indicated an increase in the elastic modulus when
comparing the cardiac microtissue with the hiPSC–CM; which
may be related to the observed ECM deposition, concordantly
to previous studies with multicellular cardiac patches (Stevens
et al., 2009). Overall, the elastic modulus estimated for the
cardiac microtissue is within the range of values reported
for the human cardiac muscle (10–15 kPa; Mathur et al.,
2016; Kofron and Mende, 2017; Dunn and Palecek, 2018).
Further optimization of this cardiac microtissue can be evaluated
by extending the time in culture to increase microtissue
maturation or by improving the complexity/functionalization
of the biomaterial used for microencapsulation (Dalheim
et al., 2019), as previously studied in other cellular models
(Almeida et al., 2017). In the future, a time-resolved analysis
of the topographical and physical changes of the cardiac
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microtissue would be beneficial for the characterization of
the profiles along time and identification of the culture
timepoint where a better recapitulation of the human cardiac
microenvironment would occur.
The microencapsulated hiPSC–based cardiac microtissues
displayed functional calcium signaling, as well as positive
response to known cardiotoxins. A recent study using 3D
hiPSC–derived cardiac microtissues has reported an IC50
16 µM for doxorubicin (Archer et al., 2018), which is the
same magnitude but lower when compared to our results
for the hiPSC–CM control (approximately 56 µM). More
importantly, our results show that there seems to be a
significant difference in the doxorubicin resistance comparing
the hiPSC–CM and the cardiac microtissue, because the
cardiac microtissue viability was maintained up to 50 µM
and only demonstrated a drop at 100 µM (not reaching the
IC50). This result might suggest that the co-culture of the
different cell types in this configuration contributed to drug
resistance, to some extent, although further testing should
be performed with additional hiPSC lines. Indeed, a study
from Burridge and coauthors showed that patient-specific
hiPSC–CM can recapitulate the predilection to doxorubicin-
induced cardiotoxicity of individual patients at the cellular
level (Burridge et al., 2016), strengthening the importance of
genetically diverse hiPSC–derivatives for cardiotoxic studies
in future studies. In contrast, the same difference was not
observed in paclitaxel exposure, indicating a drug-dependent
response. A study from the same group has also generated a
“cardiac safety index” to reflect the cardiotoxicities of existing
tyrosine kinase inhibitors, using individual populations of
hiPSC–CM, hiPSC–EC, and hiPSC–CF (Sharma et al., 2017).
Our designed cardiac microtissue may be used to complement
these toxicological screenings, enabling the inclusion of the
effect of paracrine interaction between the different cellular
compartments and may also be applied for pathophysiological
studies, similarly to recently published reports incorporating
diseased cells (Giacomelli et al., 2020).
In this study, we demonstrated the application of alginate
microencapsulation technology for cardiac tissue modeling
where the cardiac cell populations were generated using
protocols that were reported to ensure high differentiation
efficiency and robustness across different hiPSC lines (Giacomelli
et al., 2017; Correia et al., 2018). Although we performed
two independent differentiation runs with one hiPSC line,
additional studies with replicate differentiation batches of
multiple hiPSC lines are needed to validate the robustness
of the cardiac microtissue model. We believe that this
very flexible system can be combined with several other
reported hiPSC–CM maturation techniques, such as medium
supplementation or biomaterial functionalization (or even
by using starting material, which is already in advanced
state of maturation) to achieve higher hiPSC–CM functional
maturation and recapitulation of cardiac microenvironment.
Because our microtissue model focused mainly on the paracrine
interaction between the different cardiac cell populations,
further studies are needed to understand if direct cell–cell
communication would have an impact in the phenotypic
and functional features of the cardiac microtissue model. In
particular, the extension of the culture time, functionalization
of the alginate microcapsule, and/or screening of different
hiPSC lines might be evaluated and optimized to promote
cell migration and physical interaction between CM and
stromal cell. Nevertheless, this study is a step forward on the
development of a biologically relevant hiPSC–derived cardiac
microtissue that recapitulates features of the human cardiac
microenvironment and is compliant with the larger numbers
needed for pharmacological screenings.
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